蛋白酶體抑制劑（PI）市場：現況分析與預測（2023-2030）

Proteasome Inhibitors Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年02月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 156 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於老年人口的增加，蛋白酶體抑制劑（PI）市場預計將穩定成長約8.01%。隨著人口老化，多發性骨髓瘤的盛行率預計會增加。例如，根據 2021 年 2 月的 Frontiers 雜誌報導，由於人口老化，未來 20 年多發性骨髓瘤的盛行率預計每年將大幅增加 80%。在預測期內，有幾個因素正在推動市場成長，例如胰臟癌發病率的急劇上升、人們對癌症的認識不斷提高以及對腫瘤學的投資增加。除此之外，蛋白酶體抑制劑（PI）治療效率的加速促使治療過程更快、更準確，這也穩定地推動了蛋白酶體抑制劑（PI）市場的發展。

市場依給藥途徑分為口服、靜脈注射及其他。2022年全球蛋白酶體抑制劑（PI）市場中，由於患者對口服藥物的需求增加，口服藥物佔最大佔有率。據報道，片劑是所有劑型中消費最多的固體劑型，因為其高效的成分和易於消費。口服給藥正在推動這一領域的成長，因為它對消費者來說更方便，也更省錢。因此，在2022年的市場上，口服製劑將在給藥途徑中佔據較大佔有率。

依適應症，市場分為套細胞淋巴瘤、多發性骨髓瘤等。由於套細胞淋巴瘤盛行率不斷上升，預計套細胞淋巴瘤細分市場將在預測期內佔據相當大的市場佔有率。例如，根據國家醫學圖書館的數據，截至 2023 年 7 月，套細胞淋巴瘤 (MCL) 的年發生率為 20 萬分之一。MCL 在男性中更常見（3 比 1），診斷時的中位數年齡通常為 60 至 70 歲。套細胞淋巴瘤是非何傑金氏淋巴瘤的一種，是一種始於淋巴球的癌症。它特別影響 B 細胞，並且經常影響淋巴結、脾臟、骨髓和血液。套細胞淋巴瘤以其侵襲性而聞名。因此，在所有適應症中，套細胞淋巴瘤類別預計在預測期內表現出最高的複合年增長率。

為了更瞭解蛋白酶體抑制劑（PI）的市場介紹，將市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞太地區（中國、日本、印度、亞太地區其他地區）以及世界其他地區。由於老年人口增加、開發有效蛋白酶體抑制劑 (PI) 的投資增加，北美在 2022 年目前的情況下將主導市場。隨著癌症患者比例的增加，政府機構在該地區啟動了癌症意識計畫。例如，根據美國癌症協會的數據，2024 年美國將診斷出約 35,780 例多發性骨髓瘤新病例（男性 19,520 例，女性 16,260 例）。因此，依地區劃分，北美將在 2022 年佔據較大市場佔有率。

Proteasome inhibitors constitute a drug class employed in the treatment of certain blood cancers, notably multiple myeloma and mantle cell lymphoma. These inhibitors disrupt the normal protein degradation process in cancer cells by interfering with proteasomes, and cellular structures responsible for breaking down proteins. Consequently, the accumulation of proteins occurs, leading to cell death. The proteasome inhibitor market has seen steady growth in recent years due to several factors, such as increasing incidence of cancer, rising research & development activities, increasing awareness and diagnosis of cancer, rising healthcare expenditure, rising regulatory support, and surge in company collaborations & partnerships are leading drivers of proteasome inhibitors globally.

The Proteasome Inhibitors Market is expected to grow at a steady rate of around 8.01% owing to the increasing geriatric population. As the aging population grows, the prevalence of multiple myeloma is expected to rise. For instance, in February 2021, according to the Frontiers, the prevalence of multiple myeloma is projected to rise substantially at an estimated 80% per year in the next 20 years because of an aging population. Several factors, including a surge in the incidence of pancreatic cancer, increasing awareness regarding cancer, and increased investments in oncology departments are driving the market's growth during the forecast period. Apart from this, accelerated treatment efficiency with proteasome inhibitors has resulted in faster treatment procedures and better accuracy which is also driving this market of proteasome inhibitors at a steady rate.

Based on the mode of administration, the market is segmented into oral, intravenous, and others. The oral segment held the maximum share in the global market of proteasome inhibitors in 2022 owing to the rising demand for oral drugs among patients. Tablets are reported to be the most consumed solid dosage forms among all medication forms, because of their highly effective composition, and ease of consumption. The oral mode of drug administration is much more convenient and easier on pockets for the consumers which is boosting this segment's growth. Thus, among the modes of administration, the oral segment held a significant share of the market in 2022.

Based on indication, the market is categorized into mantle cell lymphoma, multiple myeloma, and others. The mantle cell lymphoma segment is expected to hold a significant share of the market in the forecast period owing to the rising prevalence of mantle cell lymphoma. For instance, in July 2023, according to the National Library of Medicine, mantle cell lymphoma (MCL) had an annual incidence of one case per 200,000 people. MCL is more common in men (3 to 1), and the median age at diagnosis usually ranges from 60 to 70 years old. Mantle cell lymphoma is a type of non-Hodgkin lymphoma, a cancer that originates in the lymphocytes. It specifically affects B cells and often involves the lymph nodes, spleen, bone marrow, and blood. Mantle cell lymphoma is known for its aggressive nature. Thus, amongst indications, the mantle cell lymphoma category is expected to witness a higher CAGR during the forecast period.

For a better understanding of the market adoption of proteasome inhibitors, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing geriatric population, and rising number of investments in developing effective proteasome inhibitors. Government organizations are initiating cancer awareness programs for the sake of the growing rate of cancer cases in the region. For instance, according to the American Cancer Society, about 35,780 new multiple myeloma cases will be diagnosed (19,520 in men and 16,260 in women) in the U.S. in the year 2024. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; Takeda Pharmaceutical Company Limited; TG Therapeutics; Pfizer Inc.; QLi5 Therapeutics GmbH; Baxter; GSK plc.; Kezar Life Sciences Inc.

1. MARKET INTRODUCTION

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

2.1.Research Process of the Proteasome Inhibitors Market
2.2.Research Methodology of the Proteasome Inhibitors Market
2.3.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE PROTEASOME INHIBITORS MARKET

6. PROTEASOME INHIBITORS MARKET REVENUE (USD BN), 2020-2030F

7. MARKET INSIGHTS BY MODE OF ADMINISTRATION

7.1.Oral
7.2.Intravenous
7.3.Others

8. MARKET INSIGHTS BY INDICATION

8.1.Mantle Cell Lymphoma
8.2.Multiple Myeloma
8.3.Others

9. MARKET INSIGHTS BY REGION

9.1.North America
- 9.1.1.U.S.
- 9.1.2.Canada
- 9.1.3.Rest of North America
9.2.Europe
- 9.2.1.Germany
- 9.2.2.U.K.
- 9.2.3.France
- 9.2.4.Italy
- 9.2.5.Spain
- 9.2.6.Rest of Europe
9.3.Asia-Pacific
- 9.3.1.China
- 9.3.2.Japan
- 9.3.3.India
- 9.3.4.Rest of Asia-Pacific
9.4.Rest of World